Edwards Lifesciences Corp (EW)vsLENSAR Inc (LNSR)
EW
Edwards Lifesciences Corp
$91.78
+1.06%
HEALTHCARE · Cap: $49.92B
LNSR
LENSAR Inc
$5.97
+0.84%
HEALTHCARE · Cap: $74.58M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 10706% more annual revenue ($6.51B vs $60.26M). LNSR leads profitability with a 57.6% profit margin vs 15.4%. LNSR trades at a lower P/E of 33.7x. LNSR earns a higher WallStSmart Score of 56/100 (C).
EW
Buy55
out of 100
Grade: C
LNSR
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.5%
Fair Value
$251.45
Current Price
$91.78
$159.67 discount
Margin of Safety
-85.9%
Fair Value
$6.68
Current Price
$5.97
$0.71 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Every $100 of equity generates 36 in profit
Keeps 58 of every $100 in revenue as profit
Conservative balance sheet, low leverage
18.4% revenue growth
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bull Case : LNSR
The strongest argument for LNSR centers on Return on Equity, Profit Margin, Debt/Equity. Profitability is solid with margins at 57.6% and operating margin at 12.9%. Revenue growth of 18.4% demonstrates continued momentum.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.5x leaves little room for execution misses.
Bear Case : LNSR
The primary concerns for LNSR are P/E Ratio, EPS Growth, Market Cap.
Key Dynamics to Monitor
EW profiles as a mature stock while LNSR is a growth play — different risk/reward profiles.
LNSR carries more volatility with a beta of 0.95 — expect wider price swings.
LNSR is growing revenue faster at 18.4% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
LNSR scores higher overall (56/100 vs 55/100), backed by strong 57.6% margins and 18.4% revenue growth. EW offers better value entry with a 68.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →LENSAR Inc
HEALTHCARE · MEDICAL DEVICES · USA
LENSAR, Inc., a commercial stage medical device company, is focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company is headquartered in Orlando, Florida.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?